U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Submitted by Anonymous on

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for zipalertinib for the treatment of patients with locally advanced...

U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Submitted by Anonymous on

PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass., April 28, 2026--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for...

Post-marketing safety surveillance of EGFR-targeted agents and disseminated intravascular coagulation risk: a disproportionality analysis based on the FDA Adverse Event Reporting System

Submitted by Anonymous on

AbstractIntroduction The epidermal growth factor receptor (EGFR) serves as a principal therapeutic target in oncology, with EGFR inhibitors representing essential agents in cancer treatment. Although thrombotic complications related to EGFR inhibitors have been reported in the literature, the evidence remains...

Fused Imidazo[1,2-a]pyrimidines Containing 1,2,3-Triazoles and Isoxazoles: One-Pot Synthesis, Anticancer, and EGFR-Inhibitory Activities

Submitted by Anonymous on

Abstract Objective: A series of imidazo[1,2-a]pyrimidine derivatives containing 1,2,3-triazoles and isoxazoles were synthesized, and their anticancer activity against lung cancer was evaluated. Methods: The one-pot reaction of (Z)-N-(4-iodobut-3-yn-2-ylidene)-1H-imidazol-2-amine III with various nitrile oxides and aryl azides, proceeding via in situ...

ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma

Submitted by Anonymous on

AbstractBackground Icotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) widely used in the treatment of EGFR-mutant lung adenocarcinoma (LUAD). However, heterogeneous responses and the development of resistance limit durable clinical benefit. The molecular regulators that...

Estrogen Receptor-α36 Mediates EGFR-SGK1 Signaling-Related Erk Activation in Gastric Cancer

Submitted by Anonymous on

This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle Estrogen Receptor-α36 Mediates EGFR-SGK1 Signaling-Related Erk Activation in Gastric Cancer by Yibo ZhangYibo Zhang SciProfiles Scilit Preprints.org Google Scholar 1,2,†, Hongyan...

Subscribe to Newsfeed